Kornimate/medical-research-clean huggingface dataset:
immunity to measles virus in the thai population age 18-30 years and predictive factors

Conditions: Measles

Summary: prevalence of participants who have protective immunity to measles virus is less than ninety percent. predictor of adequate measles antibody levels include the following : * history of measles infection * history of complete measles primary immunization( 2 doses with at least 1 month interval after age of 9 months) * history of measles exposure predictor of inadequate measles antibody levels include the following : * born outside thailand * history of staying outside thailand for long time in childhood * living in the rural area for a long period in childhood * fail to participate school system on time


Eligibility criteria:
inclusion criteria: * age 18-30 years old exclusion criteria: * last measles vaccination less than 10 years of age * immunocompromised host including congenital immune defect, splenectomy or splenic dysfunction, history of suspect hiv exposure, taking immunosuppressant * receiving blood or blood product within 3 months * receiving others vaccinations or immunoglobulins or any medication that possibly decrease immune response

Keywords: measles antibody prevalence predictors donor of national blood centre, the thai red cross society who age 18-30 years old measles antibody levels predictors of adequate measles antibody levels and inadequate measles antibody levels
clinical comparison of two daily disposable toric lenses

Conditions: Myopia; Astigmatism

Summary: the purpose of this trial was to compare the performance of two contact lenses commercially available for people with astigmatism.

this trial compared the performance of two commercialized daily disposable contact lenses in germany.

Eligibility criteria:
inclusion criteria: * sign written informed consent. * germany: be of legal age. * current monthly or weekly toric soft lens wearer able to be fit in both eyes with soft toric lenses in the study parameters. * other protocol-defined inclusion criteria may apply. exclusion criteria: * eye injury or surgery within twelve weeks. * pre-existing ocular irritation that would preclude contact lens fitting. * currently enrolled in an ophthalmic clinical trial. * wears contact lenses overnight while sleeping. * habitual daily disposable contact lens wearer. * monovision correction during the study. * other protocol-defined exclusion criteria may apply.
eltrombopag for the prevention of chemotherapy induced thrombocytopenia

Conditions: Sarcoma, Soft Tissue; Osteosarcoma; Neoplasms, Connective and Soft Tissue

Summary: the purpose of this study is to study the effect of eltrombopag on chemotherapy induced thrombocytopenia. thrombocytopenia is when there is a low number of platelets in the blood. sometimes, thrombocytopenia occurs as a side effect of chemotherapy treatments.

the combination chemotherapy regimen of gemcitabine and docetaxel has become an increasingly used treatment choice for subjects with advanced sarcomas. the regimen has shown activity in first and second line for subjects with metastatic uterine leiomyosarcoma, relapsed/refractory pediatric sarcomas, and improved progression-free survival and overall survival in persons with metastatic sarcoma when compared to gemcitabine alone. the regimen has additionally been recognized as a treatment option for subjects with advanced sarcoma. chemotherapy-induced toxicity in the blood such as low platelet level is a common and often therapy-limiting side effect of treatment. there are two phases in this study. the purpose of the phase i study is to determine the recommended dose of eltrombopag. the purpose of the phase ii study is to determine the safety, tolerability, and efficacy (how well the drug works) of eltrombopag in subjects who are receiving gemcitabine and docetaxel chemotherapy. eltrombopag (promacta) is an fda approved drug for the treatment of chronic idiopathic thrombocytopenic purpura (itp)- a condition of having an abnormally low platelet count. eltrombopag is now being further investigated for other thrombocytopenic (low platelet)disorders. participants will take the assigned dose of eltrombopag once a day starting five days before each cycle of chemotherapy and for 5 days after chemotherapy. eltrombopag is not taken on the day of chemotherapy. eltrombopag is taken orally.

Eligibility criteria:
inclusion criteria: * metastatic soft tissue or bone sarcoma * 18 years of age or older * adequate blood counts * adequate kidney and liver function * at least 1 but no more than 3 prior systemic therapy regimens for this cancer * good performance status - able to carry out work of a light or sedentary nature exclusion criteria: * pre-existing hear disease such as congestive heart failure, or arrhythmia known to increase the risk of thromboembolic events (blood clots) * blood clot in the last 6 months, known clotting problem or platelet disorder * history of brain cancer

Keywords: metastatic sarcoma bone sarcoma
effect of i31 probiotic on lactose intolerance

Conditions: Lactose Intolerance

Summary: this randomized study evaluates the usefulness of the i31 probiotic formula, against placebo, in the treatment of symptoms of lactose intolerance.

people with lactose intolerance are unable to fully digest the sugar (lactose) in milk. as a result, they may have diarrhea, abdominal pain, gas and bloating after eating or drinking dairy products. a deficiency of lactase - an enzyme produced in your small intestine - is usually responsible for lactose intolerance. many people have low levels of lactase but are able to digest milk products without problems. in lactose intolerance, though, lactase deficiency leads to symptoms after eating dairy foods. i31 is a probiotic formula composed of pediococcus acidilactici strain cect7483 and lactobacillus plantarum strains cect7484 and cect7485, previously shown to improve intestinal sensitivity in patients with irritable bowel syndrome (ibs). ibs is a functional intestinal disease in which recurrent abdominal pain is associated with defecation or a change in bowel habits, often accompanied by bloating. given the overlap in symptoms between ibs and lactose intolerance, it is hypothesized that i31 formula could be beneficial for individuals with lactose intolerance.

Eligibility criteria:
inclusion criteria: * subjects attending hospital juarez de mexico with self-reported lactose intolerance, a minimum lactose intolerance symptom score of 6 points, 20ppm during the lactose hydrogen breath test (lhbt) and providing informed consent. exclusion criteria: * more than 10 ppm before ingestion of lactose in the lactose hydrogen breath test (lhbt). if such value was observed, the lhbt test was repeated on a 2nd day, and if \>10ppm persisted, patient was excluded. * bmi below 18 or above 40 * subjects not accepting to maintain their dietary and physical activity pattern unchanged for the duration of the study * subjects with congenital lactase deficiency * pregnant or lactating women * significant gastrointestinal disease, such as inflammatory bowel disease, coeliac disease, chronic diarrhea or gastroparesis * history of gastrointestinal surgery in the 6 months prior to inclusion * history of intestinal perforation * history of acute gastroenteritis, acute gastroenteritis or hospitalization in the 4 weeks prior to inclusion * substance abuse * untreated thyroid disorder * cancer * other severe diseases that in the doctor's opinion could interfere with the study * known allergy to any of the components in the treatments

Keywords: probiotic diarrhea abdominal pain flatulence
validation of a novel sham cervical spinal manipulation procedure

Conditions: Chronic Neck Pain

Summary: primary hypotheses: ho1: in chronic neck pain patients, randomly treated with either a "sham" or "real" cervical manipulation procedure, the probability of perceiving a real manipulation procedure is equal to the probability of obtaining a real manipulation procedure, and, ho2: spinal tenderness will remain unchanged following the treatment procedure for both groups. secondary (null) hypotheses: 1. neck pain, cervical ranges of motion and paraspinal emg responses to pressure pain will remain unchanged in both groups; 2. there will be no differences between groups with respect to 2a) neck joint cavitations and 2b) forces across the cervical spine measured during the manoeuvres.

1. develop a randomized controlled clinical trial design to optimize the testing of the effects of a sham vs real cervical manipulation. 2. use novel modifications of both a sham a real manipulation to create "procedures" designed to optimize group equivalence in the rct design. then, evaluate the accuracy of 'patient post-treatment perception of treatment type' versus actual administered treatment (primary outcome #1). 3. quantitatively evaluate group differences in local soft-tissue tenderness by algometry (primary outcome #2), as well as changes in self-reported neck pain, ranges of motion, myoelectric responses in selected neck muscles and forces imparted during the procedures. 4. evaluate the occurrence of neck joint cavitation during the manoeuvres comprising these procedures.

Eligibility criteria:
inclusion criteria: * 21-55 years old with chronic neck pain, males/females * between 30-60 nrs 101 scale * ≥ 4 weeks mechanical neck pain exclusion criteria: * cervical spine surgery * medically uncontrolled high blood pressure * past history of stroke * upper respiratory infection within 4 weeks * current symptoms of dizziness * tinnitus, blurred vision, vertigo, sensory motor disturbance * current use of anticoagulant therapy * connective tissue disorder * primary fibromyalgia or myofascial pain * metabolic/neoplastic bone disease
autologous bone marrow concentration for rotator cuff tear

Conditions: Rotator Cuff Tear; Bone Marrow

Summary: this study aims to evaluate the effect of bone marrow concentration on healing of rotator cuff tear by comparing clinical and imaging outcomes between patients receiving arthroscopic repair with intraoperative bone marrow concentration and those receiving arthroscopic repair only.

rotator cuff tear is a common cause of pain and disability among adults. most tears are largely caused by the normal wear and tear that goes along with aging. although nonsurgical treatment relieves pain and improves function in the shoulder, surgical repair for a torn rotator cuff is indicated if symptoms persisted or deteriorated after 3 months nonsurgical treatments, recently, arthroscopic repair has become the mainstream of surgical repair for rotator cuff tear. however, the healing of a repaired tendon is not always predictable. mesenchymal stem cells (mscs) are pluripotent cells that can differentiate into multiple mesenchymal tissues, including tenocytes, chondrocytes and osteoblasts, as well as being a source of multiple growth factors to establish an environment conducive to soft and hard tissue regeneration. as bone marrow concentration has high concentration of mesenchymal stem cells, some studies have shown that autologous bone marrow concentration can improve the healing of tendon grafts in a bone tunnel. therefore, the goal of this study was to evaluate the effect of bone marrow concentration on healing of rotator cuff.

Eligibility criteria:
inclusion criteria: * with diagnosis of rotator cuff tear * age between 40 and 70 years exclusion criteria: * with prior history of shoulder surgery * with current or prior history of trauma or infection at shoulder * with current diagnosis of coagulopathy * with current or prior history of cancer * with current or prior history of hematological disease * pregnancy * patients who will not cooperate with one-year followup

Keywords: bone marrow mesenchymal stromal cells rotator cuff tear
contribution of the evaluation of body composition by connected scale in the effectiveness of a reconditioning program through physical activity adapted for patients suffering from chronic diseases

Conditions: Chronic Disease

Summary: the goal of this interventional study is to evaluate the impact of the use of a connected impedance scale on the physical and mental quality of life of patients suffering from chronic diseases and participating in a physical activity rehabilitation program. the main objective is to know if a regular monitoring of the evolution of body composition parameters recorded by the connected scale would allow patients participating in the physical activity rehabilitation program at hôtel-dieu to follow in real time the effects of such program, not on weight itself but on body composition, and that this would contribute to a better perception of physical and mental quality of life at the end of the program 90 participants will be randomized in two groups : * control group (n = 45) : routine care * interventionnal group (n=45) : routine care + use of connected scale all participants will undergo physical activity rehabilitation program during 6 weeks. patients will be see again at 6 months, and the following parameters will be comparer between the two groups : * sf-36 questionnaire * ricci \& gagnon questionnaire * 6mwt * 30 sec sit-to stand test * ito-shirado test * sorensen test * handgrip test * maxv02


Eligibility criteria:
inclusion criteria: * patient (male or female) aged 18 and over * patient able to express free, informed and written consent * patient participating in the physical activity rehabilitation program at the cims of the hôtel dieu * patient suffering from a known, stable and diagnosed chronic disease * patient autonomous in taking treatments for their ald * patient affiliated to a social security system exclusion criteria: * patient under legal protection (guardianship, curatorship) * patient deprived of liberty by a judicial or administrative decision * patient with functional limitations that do not allow a physical assessment or result in a walking distance \< 350 m during the hdj for admission to the program * patient with suspected cardiac pathology during the hdj for admission to the program * patient with episode of decompensation or exacerbation * patient with a pacemaker or implantable automatic defibrillator * pregnant women

Keywords: physical activity rehabilitation program connected scale
retrospective wgs study

Conditions: Cancer; Pediatric Cancer; Neoplasm

Summary: this retrospective case series reviews clinical notes to assess whether nhs whole genome sequencing provides tangible benefits for paediatric tumours.

the nhse-commissioned whole genome sequencing programme went live at the end of 2020. it remains as yet unproven, whether this whole genome sequencing programme for children with cancer can deliver tangible benefits in real-time. there is an urgent need, therefore, to assess whether children with tumours who are receiving nhs whole genome sequencing are actually benefiting from this additional assay. this is a retrospective case series. the principal methodology is that of reviewing clinical notes to assess whether children with tumours have benefited from nhse whole genome sequencing. apart from the contribution of our work to the scientific literature, this research will inform government on the potential benefits, or lack thereof, of the live nhse whole genome programme and has the potential to influence policy on whether this programme should be continued.

Eligibility criteria:
inclusion criteria: * all children and young people (up to the age of 21 years) diagnosed with a neoplastic disorder who have been offered nhse whole genome sequencing. exclusion criteria: * anyone not offered nhse whole genome sequencing * individuals beyond the age of 21 * individuals without a neoplastic disorder.
technological home care: improving hpn care with videophone and internet education

Conditions: Home Parenteral Nutrition

Summary: the purpose of this study is to help people with home parenteral nutrition (hpn) to avoid infections and feelings of depression or fatigue and to test how their health and quality of life change over time. another purpose is to test the nurse teaching sessions and the method of obtaining support from the peer partner through videophone.

aim #1 hypothesis 1. dyad (patient-caregiver) participation in health care management and problem-solving method use with professionals will be greater in the experimental group than the control group 2. dyad reactive depression will be lower in the experimental group than the control group 3. dyad quality of life will be higher in the experimental group than the control group 4. dyad health status scores will be higher and the dyad sleepiness scale will be lower in experimental group than the control group 5. dyad health services use will be lower in the experimental group than the control group 6. catheter-related infections will be lower in the experimental than control patients aim #2 hypotheses: 1. what is the cost of using the famtechcare system compared to traditional care? 2. is there a difference between efficiency scores of the experimental and control groups intervention, boosters and relative to dyads long-term health services use at 24 months? 3. what are the relationships among patient outcome variables and caregivers' rating of virtual nurse caring and caregiver adaption? 4. what are the relationships among use of famtechcare, dyad participation in health care management scale score and dyad access to the internet weighted score?

Eligibility criteria:
inclusion criteria: * 18 years or older * caregivers of hpn patients short- or long-term hpn * able to participate in writing and other intervention activities * able to speak/read/write english or spanish exclusion criteria: * patients with psychiatric disorders (e.g., schizophrenia, hallucinations) and physical disabilities that prevent use of intervention

Keywords: home parenteral nutrition
real world study on first line crizotinib in ros1 rearranged advanced non-squamous non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: this study was designed to explore the efficacy and safety of crizotinib as a first-line treatment for advanced nsclc with ros1 rearrangement positive mutation in the real world, explore the new drug resistance mechanism of ros1 under crizotinib treatment and the consistency of plasma and tissue detection driving genes, and finally evaluate the mutation spectrum of plasma dynamic detection driving genes. in predicting the risk of disease progression.

this is a research project involving patients in medical oncology department of affiliated cancer hospital of xiangya school of medicine central south university. retrospective study of 40 patients with advanced non-squamous non-small cell lung cancer (nsclc) using crizotinib ros1 rearrangement positive mutation was conducted to observe the efficacy and safety of crizotinib regimen in the real world.exploratory research contents are as follows: 1. consistency between tissue gene test (ngs) and plasma gene test (ngs) at the initial diagnosis; 2. consistency between ngs and plasma gene test (ngs) at the progression of clozotinib treatment; 3. drug resistance mechanism of clozotinib in ros1 rearrangement positive nsclc; 4. plasma drug resistance. large panel dynamic driven gene mutation analysis was used to construct disease progression risk model.

Eligibility criteria:
inclusion criteria: * ≥18，advanced non-squamous non-small cell lung cancer confirmed by histopathology * ros1 arranged positive * ros1 arranged detection method is ngs * first diagnosis and treatment * treatment plan is kazolinib 250mg po bid exclusion criteria: * patients received antitumor treatment before * patients with contraindication of chemotherapy * pregnant or breast feeding women

Keywords: non-small cell lung cancer crizotinib ros1 rearranged
paraprofessional treatment of depression in vietnam

Conditions: Depressive Symptoms

Summary: trained para-professional health care workers will implement a stepped-care model of depression care in commune health stations in vietnam.

this project focuses on evaluation of a collaborative care system for treatment of depression in vietnam. this system involves training para-professional health care workers in a stepped-care model system of depression care to be implemented in commune health stations in vietnam.

Eligibility criteria:
inclusion criteria: 1. age \>=18 2. depression diagnosis exclusion criteria: active psychosis, mania, substance abuse, suicidal behaviors, cognitive impairment.

Keywords: depression collaborative care vietnam behavioral activation
a pilot study of chlorthalidone among patients with poorly controlled hypertension and ckd

Conditions: Chronic Kidney Disease; Poorly-Controlled Hypertension

Summary: it is estimated that in the united states there are approximately 8 million individuals with moderate to severe chronic kidney disease (ckd), not on dialysis. volume expansion plays an important role in the pathogenesis of hypertension in patients with ckd. for this pilot study, the investigators hypothesize that administration of chlorthalidone among patients with moderate to severe ckd will improve blood pressure (bp).


Eligibility criteria:
inclusion criteria: * age greater than 18 years. * estimated glomerular filtration rate (egfr) ≤ 45 ml/min/1.73m2 but ≥20 ml/min/1.73m2. * poorly controlled blood pressure by 24-hour ambulatory blood pressure (bp) monitoring. * treated hypertension: use of at least one antihypertensive drug. one of the drugs should be either an angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb). if these are contraindicated then use of a beta-blocker is required. exclusion criteria: * use of thiazide or thiazide-like drugs in the previous 3 months. * use of furosemide in a dose \>200 mg/d. * ambulatory bp of either ≥160 systolic or ≥100 mmhg by 24-hour ambulatory bp monitoring. * expected to receive renal replacement therapy within the next 3 months. * vascular event such as myocardial infarction, heart failure hospitalization, or stroke within 3 months prior to randomization. * pregnant or breastfeeding women or women who are planning to become pregnant or those not using a reliable form of contraception (oral contraceptives. condoms and diaphragms will be considered reliable). * known hypersensitivity to thiazide or sulfa drugs. * organ transplant recipient or therapy with immunosuppressive agents. nasal or inhaled corticosteroids will be permitted.

Keywords: hypertension kidney disease